PubMed:16177264 / 1568-1788 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T10","span":{"begin":0,"end":220},"obj":"Sentence"},{"id":"T10","span":{"begin":0,"end":220},"obj":"Sentence"},{"id":"T10","span":{"begin":0,"end":220},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"Glycosmos6-MAT","denotations":[{"id":"T7","span":{"begin":204,"end":212},"obj":"http://purl.obolibrary.org/obo/MAT_0000078"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"uniprot-human","denotations":[{"id":"T13","span":{"begin":41,"end":44},"obj":"http://www.uniprot.org/uniprot/P07288"},{"id":"T27","span":{"begin":41,"end":44},"obj":"http://www.uniprot.org/uniprot/Q9Y617"},{"id":"T39","span":{"begin":41,"end":44},"obj":"http://www.uniprot.org/uniprot/P55786"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"uniprot-mouse","denotations":[{"id":"T12","span":{"begin":41,"end":44},"obj":"http://www.uniprot.org/uniprot/Q11011"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"GO-BP","denotations":[{"id":"T4","span":{"begin":62,"end":66},"obj":"http://purl.obolibrary.org/obo/GO_0004617"},{"id":"T11","span":{"begin":24,"end":37},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"GlycoBiology-MAT","denotations":[{"id":"T7","span":{"begin":204,"end":212},"obj":"http://purl.obolibrary.org/obo/MAT_0000078"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"Lectin","denotations":[{"id":"Lectin_T12","span":{"begin":41,"end":44},"obj":"https://acgg.asia/db/lfdb/LfDB0181"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"mondo_disease","denotations":[{"id":"T17","span":{"begin":50,"end":53},"obj":"Disease"},{"id":"T18","span":{"begin":58,"end":61},"obj":"Disease"}],"attributes":[{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0008315"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0010811"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"Anatomy-MAT","denotations":[{"id":"T7","span":{"begin":204,"end":212},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"mat_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MAT_0000078"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"HP-phenotype","denotations":[{"id":"T15","span":{"begin":50,"end":53},"obj":"Phenotype"},{"id":"T16","span":{"begin":58,"end":61},"obj":"Phenotype"}],"attributes":[{"id":"A15","pred":"hp_id","subj":"T15","obj":"HP:0012125"},{"id":"A16","pred":"hp_id","subj":"T16","obj":"HP:0008711"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"GlyCosmos15-HP","denotations":[{"id":"T15","span":{"begin":50,"end":53},"obj":"Phenotype"},{"id":"T16","span":{"begin":58,"end":61},"obj":"Phenotype"}],"attributes":[{"id":"A15","pred":"hp_id","subj":"T15","obj":"HP:0012125"},{"id":"A16","pred":"hp_id","subj":"T16","obj":"HP:0008711"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"GlyCosmos15-MONDO","denotations":[{"id":"T17","span":{"begin":50,"end":53},"obj":"Disease"},{"id":"T18","span":{"begin":58,"end":61},"obj":"Disease"}],"attributes":[{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0008315"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0010811"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"GlyCosmos15-UBERON","denotations":[{"id":"T11","span":{"begin":204,"end":212},"obj":"Body_part"}],"attributes":[{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0002367"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"GlyCosmos15-MAT","denotations":[{"id":"T7","span":{"begin":204,"end":212},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"mat_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MAT_0000078"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T10","span":{"begin":0,"end":220},"obj":"Sentence"},{"id":"T10","span":{"begin":0,"end":220},"obj":"Sentence"},{"id":"T10","span":{"begin":0,"end":220},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T10","span":{"begin":0,"end":220},"obj":"Sentence"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"GlyCosmos15-Lectin-Jamboree","denotations":[{"id":"T12","span":{"begin":41,"end":44},"obj":"Lectin"}],"attributes":[{"id":"A12","pred":"glycosmos_id","subj":"T12","obj":"GL_000021"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"Lectin-Jamboree-small","denotations":[{"id":"T12","span":{"begin":41,"end":44},"obj":"Lectin"}],"attributes":[{"id":"A12","pred":"glycosmos_id","subj":"T12","obj":"GL_000021"}],"namespaces":[{"prefix":"_base","uri":"https://glycosmos.org/lectins/"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"Lectin-Jamboree-Sentence","blocks":[{"id":"T10","span":{"begin":0,"end":220},"obj":"Sentence"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}

{"project":"Anatomy-UBERON","denotations":[{"id":"T11","span":{"begin":204,"end":212},"obj":"Body_part"}],"attributes":[{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0002367"}],"text":"Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states."}